Adefovir serum levels do not differ between responders and nonresponders. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Viral Hepatitis Année : 2011

Adefovir serum levels do not differ between responders and nonresponders.

K. Deterding
  • Fonction : Auteur
L. Naesens
  • Fonction : Auteur
M. Buti
  • Fonction : Auteur
H. Janssen
  • Fonction : Auteur
A. Guerrero
  • Fonction : Auteur
J. Neyts
  • Fonction : Auteur
F. Zoulim
H. Wedemeyer
  • Fonction : Auteur

Résumé

Primary or secondary failure of adefovir dipivoxil (ADV) therapy of chronic hepatitis B is not infrequent. The reasons for suboptimal responses are not well defined. In HIV and hepatitis C virus infection, failure of antiviral drug therapy has been linked with low blood drug levels. We have studied 20 well-defined patients with chronic hepatitis B who were treated with ADV for drug and virus kinetics. Importantly, neither Cmax levels (mean 26 ng/mL, range 14-59 ng/mL) nor the time to maximal drug levels (mean 4 h, range 2-8 h) differed between patients showing a complete virological response to adefovir (n = 10), patients with secondary treatment failure (n = 7) and patients with suboptimal primary response (hepatitis B virus-DNA >10,000 IU/mL after 6 months of treatment; n = 3). Thus, adefovir treatment failure is unlikely to be due to an inability to mount sufficient drug levels in the blood.

Domaines

Cancer

Dates et versions

hal-00794520 , version 1 (26-02-2013)

Identifiants

Citer

K. Deterding, L. Naesens, M. Buti, H. Janssen, J. Kirschner, et al.. Adefovir serum levels do not differ between responders and nonresponders.. Journal of Viral Hepatitis, 2011, 18 (7), pp.e175-8. ⟨10.1111/j.1365-2893.2010.01404.x⟩. ⟨hal-00794520⟩
144 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More